Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Olivier L, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: barlesi f. Eur J Cancer. 2024 May 4;205:114075. doi: 10.1016/j.ejca.2024.114075. Online ahead of print. Eur J Cancer. 2024. PMID: 38733717 Review.
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.
Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, De Martin E, Ducreux M, Even C, Le Pavec J, Michot JM, M Ribeiro J, Scotte F, Ponce Aix S, Lambotte O, Baldini C, Champiat S. Rached L, et al. Among authors: barlesi f. Cancer Treat Rev. 2024 May 4;127:102751. doi: 10.1016/j.ctrv.2024.102751. Online ahead of print. Cancer Treat Rev. 2024. PMID: 38729086 Review.
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.
Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, Gautschi O, Aboubakar F, Muñoz-Couselo E, Pierret T, Rothschild SI, Cortiula F, Reynolds KL, Thibault C, Gavralidis A, Blais N, Barlesi F, Planchard D, Besse BMD. Remon J, et al. Among authors: barlesi f. ESMO Open. 2024 Apr 22;9(5):103004. doi: 10.1016/j.esmoop.2024.103004. Online ahead of print. ESMO Open. 2024. PMID: 38653155 Free PMC article.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. Among authors: barlesi f. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial.
Walls GM, Mistry H, Barlesi F, Bezjak A, Pechoux CL, O'Brien M, Van Meerbeeck JP, Blackhall F, Faivre-Finn C. Walls GM, et al. Among authors: barlesi f. Int J Radiat Oncol Biol Phys. 2024 Mar 21:S0360-3016(24)00382-1. doi: 10.1016/j.ijrobp.2024.02.063. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38521132 Free article.
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Khushalani NI, Ott PA, Ferris RL, Cascone T, Schadendorf D, Le DT, Sharma MR, Barlesi F, Sharfman W, Luke JJ, Melero I, Lathers D, Neely J, Suryawanshi S, Sanyal A, Holloway JL, Suryawanshi R, Ely S, Segal NH. Khushalani NI, et al. Among authors: barlesi f. J Immunother Cancer. 2024 Mar 7;12(3):e007364. doi: 10.1136/jitc-2023-007364. J Immunother Cancer. 2024. PMID: 38458639 Free PMC article. Clinical Trial.
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M. Baptiste Oudart J, et al. Among authors: barlesi f. Lung Cancer. 2024 Apr;190:107508. doi: 10.1016/j.lungcan.2024.107508. Epub 2024 Feb 19. Lung Cancer. 2024. PMID: 38428265 Free article. Clinical Trial.
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G, Willekens C, Vasse M, Griscelli F, Fahrner JE, Goubet AG, Dubuisson A, Derosa L, Nirmalathasan N, Bredel D, Mouraud S, Pradon C, Stoclin A, Rozenberg F, Duchemin J, Jourdi G, Ellouze S, Levavasseur F, Albigès L, Soria JC, Barlesi F, Solary E, André F, Pène F, Ackerman F, Mouthon L, Zitvogel L, Marabelle A, Michot JM, Fontenay M, Kroemer G. Danlos FX, et al. Among authors: barlesi f. Cell Death Dis. 2024 Feb 14;15(2):142. doi: 10.1038/s41419-024-06519-7. Cell Death Dis. 2024. PMID: 38355585 Free PMC article. No abstract available.
458 results